Loading news...
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026.
Shift4 Payments' stock was down after a competitor reported disappointing results, raising concerns for the industry. While Trex Co. is facing some current challenges, we still view Trex as a high-quality business. Fabrinet is seeing increased demand as data centers upgrade their networks to faster and lower-latency communication standards capable of handling complex AI workloads.
Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript
Shares of Certara, Inc. (NASDAQ: CERT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seventeen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and two have issued
Shares of Certara, Inc. (NASDAQ: CERT - Get Free Report) gapped up before the market opened on Tuesday after Leerink Partners upgraded the stock from a market perform rating to an outperform rating. The stock had previously closed at $9.04, but opened at $9.43. Leerink Partners now has a $13.00 price target on the stock. Certara
Texas-based Kopion Asset Management added 327,064 Certara shares in the fourth quarter; the estimated transaction size is $3.37 million based on average prices for the quarter. The value of the Certara position rose by $645,681 over the quarter, reflecting both additional shares and price movement.
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.3% in Certara (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
Intech Investment Management LLC bought a new stake in Certara, Inc. (NASDAQ: CERT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,147 shares of the company's stock, valued at approximately $329,000. Several other large investors have also recently
The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were Financials and Consumer Staples. From a factor perspective, the Fund's focus on profitable, liquid, and higher quality small cap stocks negatively impacted relative performance during the quarter.
Certara, Inc. ( CERT ) Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM EST Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Jeffrey Garro - Stephens Inc., Research Division Presentation Jeffrey Garro Stephens Inc., Research Division I think we're at the top of the hour, so we'll kick it off. A big thank you to John Gallagher, CFO of Certara, for joining us today at the Stephens Investment Conference in Nashville.
Certara, Inc. ( CERT ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants William Feehery - CEO & Director Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Okay. Good morning, everybody.
Certara, Inc. ( CERT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants David Deuchler - Gilmartin Group LLC Daniel Christopher Clark - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division Kyle Crews - UBS Investment Bank, Research Division Max Smock - William Blair & Company L.L.C.
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.
RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution.
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.